A new dual-chimeric antigen receptor (CAR) system enhances the antitumor activity of CAR natural killer cells and makes them less susceptible to therapeutic #resistance in preclinical models. @lab_rezvani#CARNK#therapyresistance
https://t.co/NAMsjUD3sb